CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in India

CEL-SCI Corporation CVM announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India. Enrollment is expected to commence in the first half of May. Currently, the study has a US center at Hematology and Oncology Associates in Tupelo, Mississippi, actively recruiting patients. The Company expects enrollment in India to be substantially faster than in North America since head and neck cancer is India's leading cancer. The total study is expected to enroll a total of about 880 head and neck cancer patients in about 48 hospitals in 9 countries on three continents. CEL-SCI's partners Teva Pharmaceuticals and Orient Europharma will conduct parts of the Phase III study in Israel and Taiwan respectively.